363 NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation
نویسندگان
چکیده
منابع مشابه
Loss of heterozygosity in childhood de novo acute myelogenous leukemia.
A genome-wide screening for loss of heterozygosity (LOH), a marker for possible involvement of tumor suppressor genes, was conducted in 53 children with de novo acute myelogenous leukemia (AML). A total of 177 highly polymorphic microsatellite repeat markers were used in locus-specific polymerase chain reactions. This comprehensive allelotyping employed flow-sorted cells from diagnostic samples...
متن کاملTelomere erosion in NF1 tumorigenesis
Neurofibromatosis type 1 (NF1; MIM# 162200) is a familial cancer syndrome that affects 1 in 3,500 individuals worldwide and is inherited in an autosomal dominant fashion. Malignant Peripheral Nerve Sheath Tumors (MPNSTs) represent a significant cause of morbidity and mortality in NF1 and currently there is no treatment or definite prognostic biomarkers for these tumors. Telomere shortening has ...
متن کاملGenetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors.
Malignant peripheral nerve sheath tumors (MPNSTs), often found associated with neurofibromatosis type 1 (NF1), are aggressive tumors that pose significant diagnostic and therapeutic challenges. About 10% of NF1 patients may develop an MPNST, exhibiting a poor prognosis. With no effective treatment available, radical surgery and chemo- and radiotherapy are required to reduce tumor recurrence, me...
متن کاملOptic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity.
Whereas biallelic neurofibromatosis 1 (NF1) inactivation is observed in NF1-associated gliomas, astrocyte-restricted Nf1 conditional knockout mice do not develop gliomas. These observations suggest that NF1 glioma formation requires additional cellular or genetic conditions. To determine the effect of an Nf1 heterozygous brain environment on NF1 glioma formation, we generated Nf1+/- mice lackin...
متن کاملDe novo malignant tumors in organ transplant recipients.
FOLLOWING THE INITIAL REPORTS of de novo malignancies in transplant recipients in 1968,1-3 an informal tumor registry for such cases was established in Denver.4 To date, accounts of malignant neoplasms in 39 renal recipients have been compiled from our own program or else submitted by a number of other groups to this registry (Tables 1 and 2). One patient has developed a carcinoma of the stomac...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Investigative Dermatology
سال: 2019
ISSN: 0022-202X
DOI: 10.1016/j.jid.2019.03.439